In a packed session at Cancer Progress 2025, a group of biotech founders, pharma executives, strategists, and investors gathered to confront one of the most urgent dilemmas in oncology today: how to sustain platform-driven innovation in an environment that increasingly favors shortterm, asset-led returns.
Moderated by Jeff Bockman, EVP, Oncology and Kaitlyn Andreano, PhD, Manager of Lumanity Strategy Consulting, the session—titled “Back to the Future: Next Generation Platforms”—brought together voices from across the innovation landscape, including leaders from Moderna, Regeneron, Genmab, Scorpion Therapeutics, Candel Therapeutics, and NextRNA.
What emerged was a layered, honest, and at times uneasy look at how capital is being allocated, how risk is being managed, and what these shifts mean for the future of oncology innovation—and the patients who depend on it.
The session touched on three converging tensions:
-
How to define and capture platform value in a cautious market.
-
How to manage scientific and commercial risk across the development continuum.
-
How to adapt to global shifts in oncology innovation, including rising competition from China.
Download Full Recap
"*" indicates required fields
